Literature DB >> 8062389

ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1.

D Xu1, N Emoto, A Giaid, C Slaughter, S Kaw, D deWit, M Yanagisawa.   

Abstract

Endothelin-1 (ET-1), a 21-residue vasoactive peptide, is produced in vascular endothelial cells from the 38-residue inactive intermediate big endothelin-1 via a specific cleavage at Trp-21-Val-22. The protease that catalyzes the conversion, endothelin-converting enzyme (ECE), constitutes a potential regulatory site for the production of the active peptide. We report the identification of ECE-1, a novel membrane-bound neutral metalloprotease that is expressed abundantly in endothelial cells in vivo and is structurally related to neutral endopeptidase 24.11 and Kell blood group protein. When transfected into cultured cells that normally secrete only big ET-1, the ECE-1 cDNA conferred the ability to secrete mature ET-1. In transfected cells, ECE-1 processes endogenously synthesized big ET-1 as well as exogenously supplied big ET-1, which interacts with ECE-1 on the cell surface. ECE-1 may provide a target for pharmacological intervention to alter ET-1 production.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8062389     DOI: 10.1016/0092-8674(94)90425-1

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  146 in total

Review 1.  Secretory pathways in endothelin synthesis.

Authors:  F D Russell; A P Davenport
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

Review 2.  Hypophosphatemic rickets.

Authors:  L A DiMeglio; M J Econs
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

Review 3.  Effects of antihypertensive drugs on endothelial dysfunction: clinical implications.

Authors:  Stefano Taddei; Agostino Virdis; Lorenzo Ghiadoni; Isabella Sudano; Antonio Salvetti
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension.

Authors:  H Reynaert; M G Thompson; T Thomas; A Geerts
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

5.  Characterization of PHEX endopeptidase catalytic activity: identification of parathyroid-hormone-related peptide107-139 as a substrate and osteocalcin, PPi and phosphate as inhibitors.

Authors:  G Boileau; H S Tenenhouse; L Desgroseillers; P Crine
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

6.  The role of endothelin in the pathogenesis of heart failure.

Authors:  John R Teerlink
Journal:  Curr Cardiol Rep       Date:  2002-05       Impact factor: 2.931

7.  Differential glial and vascular expression of endothelins and their receptors in rat brain after neurotrauma.

Authors:  A L Sirén; F Knerlich; L Schilling; H Kamrowski-Kruck; A Hahn; H Ehrenreich
Journal:  Neurochem Res       Date:  2000-07       Impact factor: 3.996

8.  Secretion of endothelin converting enzyme-1a: the hydrophobic signal anchor domain alone is not sufficient to promote membrane localization.

Authors:  S C Brooks; L Fernandez; A Ergul
Journal:  Mol Cell Biochem       Date:  2000-05       Impact factor: 3.396

Review 9.  Drug Treatment of Hypertension: Focus on Vascular Health.

Authors:  Alan C Cameron; Ninian N Lang; Rhian M Touyz
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

10.  mef2ca is required in cranial neural crest to effect Endothelin1 signaling in zebrafish.

Authors:  Craig T Miller; Mary E Swartz; Patricia A Khuu; Macie B Walker; Johann K Eberhart; Charles B Kimmel
Journal:  Dev Biol       Date:  2007-05-24       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.